CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

Core Insights - CorMedix Inc. is set to report its financial results for Q2 2024 on August 14, 2024, before market opening [1] - The company will host a corporate update conference call at 8:30 AM Eastern Time on the same day [1] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [2] - The company's lead product, DefenCath®, received FDA approval on November 15, 2023, and was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [2] - CorMedix plans to develop DefenCath as a catheter lock solution for additional patient populations [2]